The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Axonal degeneration in Alzheimer's disease: When signaling abnormalities meet the axonal transport system
Open accessAbstract
Alzheimer’s disease (AD) is characterized by progressive, age-dependent degeneration of neurons in the central nervous system. A large body of evidence indicates that neurons affected in AD follow a dying-back pattern of degeneration, where abnormalities in synaptic function and axonal connectivity long precede somatic cell death. Mechanisms underlying dying-back degeneration of neurons in AD remain elusive but several have been proposed, including deficits in fast axonal transport (FAT). Accordingly, genetic evidence linked alterations in FAT to dying-back degeneration of neurons, and FAT defects have been widely documented in various AD models. In light of these findings, we discuss experimental evidence linking several AD-related pathogenic polypeptides to aberrant activation of signaling pathways involved in the phosphoregulation of microtubule-based motor proteins. While each pathway appears to affect FAT in a unique manner, in the context of AD, many of these pathways might work synergistically to compromise the delivery of molecular components critical for the maintenance and function of synapses and axons. Therapeutic approaches aimed at preventing FAT deficits by normalizing the activity of specific protein kinases may help prevent degeneration of vulnerable neurons in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 1×
“Amyloid-β and Phosphotransferase Misregulation Since the identification of Aβ as the major constituent of senile plaques in AD brains, Aβ has been considered a central player in AD pathogenesis (Benilova et al., 2012).”
BackgroundReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Cited by
The Neuropathology and Neurobiology of Traumatic Brain Injury
Blennow, K., Hardy, J., & Zetterberg, H. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.021 · Cited by 669
Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies
Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509
Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Mietelska-Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 404
Liquid-liquid phase separation induces pathogenic tau conformations in vitro
Kanaan, N. M., Hamel, C., Grabinski, T., & Combs, B. (2020) · Nature Communications · doi:10.1038/s41467-020-16580-3 · Cited by 397
Self-citationProtein kinase CK2: a potential therapeutic target for diverse human diseases
Borgo, C., D’Amore, C., Sarno, S., Salvi, M., & Ruzzene, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00567-7 · Cited by 362
Ryan, N. S., Keihaninejad, S., Shakespeare, T. J., Lehmann, M., Crutch, S. J., Malone, I. B., Thornton, J. S., Mancini, L., Hyare, H., Yousry, T., et al. (2013) · Brain · doi:10.1093/brain/awt065 · Cited by 205
RNA binding proteins co-localize with small tau inclusions in tauopathy
Maziuk, B. F., Apicco, D. J., Cruz, A. L., Jiang, L., Ash, P. E. A., da Rocha, E. L., Zhang, C., Yu, W. H., Leszyk, J., Abisambra, J. F., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0574-5 · Cited by 151
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
Effects of Ashwagandha (Roots of Withania somnifera) on Neurodegenerative Diseases
Kuboyama, T., Tohda, C., & Komatsu, K. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00022 · Cited by 127
Diffusion-MRI in neurodegenerative disorders
Goveas, J., O’Dwyer, L., Mascalchi, M., Cosottini, M., Diciotti, S., De Santis, S., Passamonti, L., Tessa, C., Toschi, N., & Giannelli, M. (2015) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2015.04.006 · Cited by 104
Axonal degeneration in tauopathies: disease relevance and underlying mechanisms
Kneynsberg, A., Combs, B., Christensen, K., Morfini, G., & Kanaan, N. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00572 · Cited by 102
“…(RamirezRios et al., 2016), cytoskeleton-plasma membrane interactions (Brandt et al., 1995), RNA-binding protein and stress granule regulation (Vanderweyde et al., 2016), as well as scaffolding of phosphotransferases (Lee et al., 1998; Liao et al., 1998; Ittner et al., 2010; Kanaan et al., 2013).”
BackgroundInfluentialSelf-citationTen Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87
Murata, H., Khine, C. C., Nishikawa, A., Yamamoto, K.-I., Kinoshita, R., & Sakaguchi, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004578 · Cited by 80
Olajide, O. J., Yawson, E. O., Gbadamosi, I. T., Arogundade, T. T., Lambe, E., Obasi, K., Lawal, I. T., Ibrahim, A., & Ogunrinola, K. Y. (2017) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2017.02.010 · Cited by 79
Bhattacharyya, R., Black, S. E., Lotlikar, M. S., Fenn, R. H., Jorfi, M., Kovacs, D. M., & Tanzi, R. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109134 · Cited by 77
Rho-kinase ROCK inhibitors reduce oligomeric tau protein
Hamano, T., Shirafuji, N., Yen, S.-H., Yoshida, H., Kanaan, N. M., Hayashi, K., Ikawa, M., Yamamura, O., Fujita, Y., Kuriyama, M., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.009 · Cited by 76
Self-citationSex-specific DNA methylation differences in Alzheimer’s disease pathology
Zhang, L., Young, J. I., Gomez, L., Silva, T. C., Schmidt, M. A., Cai, J., Chen, X., Martin, E. R., & Wang, L. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01177-8 · Cited by 58
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
“, 2018), the degeneration of axons (Kandan et al., 2013), the development of type 2 diabetes mellitus (T2DM), the cerebral desensitization of growth and neurotrophic factors, in particular insulin (Gault and Holscher, 2018; Holscher, 2019), as well as alterations of the dopaminergic system, including the extensive atr…”
BackgroundOptineurin-facilitated axonal mitochondria delivery promotes neuroprotection and axon regeneration
Liu, D., Webber, H. C., Bian, F., Xu, Y., Prakash, M., Feng, X., Yang, M., Yang, H., You, I.-J., Li, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57135-8 · Cited by 34
Amyloid-beta induced retrograde axonal degeneration in a mouse tauopathy model
Nishioka, C., Liang, H.-F., Barsamian, B., & Sun, S.-W. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.01.007 · Cited by 30
Alsameen, M. H., Gong, Z., Qian, W., Kiely, M., Triebswetter, C., Bergeron, C. M., Cortina, L. E., Faulkner, M. E., Laporte, J. P., & Bouhrara, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1205426 · Cited by 29
Amaral, L. D., Santos, N. A. G. D., Sisti, F. M., Del Bel, E., & Santos, A. C. D. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109454 · Cited by 18
Ali, D. G., Abner, E. L., Bahrani, A. A., El Khouli, R., Gold, B. T., Jiang, Y., Wilcock, D. M., & Jicha, G. A. (2023) · Brain Sciences · doi:10.3390/brainsci13020218 · Cited by 6
“Aβ deposition is hypothesized as being the initial step in the neuropathological development of AD and dementia [18], but findings from previous studies have also shown that WMHs often occur prior to the presence of amyloid-β plaques in preclinical AD [19–21] supporting a retrograde degeneration hypothesis [22,23].”
ResultGong, Z., Laporte, J. P., Guo, A. Y., Bilgel, M., Bae, J., Fox, N. Y., de Rouen, A., Zhang, N., Taranath, A., de Cabo, R., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196638 · Cited by 7
“Postmortem histological studies indicate that WM degeneration, including axonal loss, is a primary consequence of aging and AD, associated with cognitive decline, motor impairments, and neurodegenerative disorders (38).”
Metadata
- Authors
- Kanaan, N. M., Pigino, G. F., Brady, S. T., Lazarov, O., Binder, L. I., & Morfini, G. A.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 246
- Pages
- 44-53
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W1967601924
- Cited by
- 212
- References
- 36
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.